Web Exclusives

News

Robotic Tumor Enucleation Appears Safe for Sporadic Renal Cell Carcinoma

The use of robotic tumor enucleation conferred favorable long-term surgical margins and local recurrence rates in patients with sporadic renal cell carcinoma (RCC), according to the results of a single-center Italian study.1 The findings were published online September 27, 2018, in Urologic Oncology. Patients undergoing robotic tumor enucleation with no ablation of the tumor bed…
prostate histologic specimen

Prostate Cancer Risk After Single Negative Biopsy Quantified

Almost one quarter of men who have a single negative prostate biopsy are eventually diagnosed with prostate cancer (PCa) within 20 years, according to investigators. The finding is from a study of 95,675 men who had a negative first transrectal ultrasound (TRUS)-guided prostate biopsy from January 1994 to October 2014. The 5-, 10-, 15, and…
US Food and Drug Administration

Herceptin Hylecta Approved for the Treatment of HER2-Overexpressing Breast Cancer

The Food and Drug Administration (FDA) has approved Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) for the treatment of HER2-overexpressing breast cancer. Herceptin Hylecta is a combination of trastuzumab, an HER2/neu receptor antagonist, and hyaluronidase, an endoglycosidase used to increase the dispersion and absorption of coadministered drugs when administered subcutaneously. The product contains the same active ingredient…
Next post in Web Exclusives